Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 1772 2022-04-01 10:37:33 |
2 format + 1 word(s) 1773 2022-04-02 03:44:22 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Molinaro, P.; Nappi, R.; , .; Bosoni, D.; Tiranini, L. Premenstrual Syndrome and Premenstrual Dysphoric Disorder. Encyclopedia. Available online: https://encyclopedia.pub/entry/21265 (accessed on 13 December 2024).
Molinaro P, Nappi R,  , Bosoni D, Tiranini L. Premenstrual Syndrome and Premenstrual Dysphoric Disorder. Encyclopedia. Available at: https://encyclopedia.pub/entry/21265. Accessed December 13, 2024.
Molinaro, Pietro, Rossella Nappi,  , David Bosoni, Lara Tiranini. "Premenstrual Syndrome and Premenstrual Dysphoric Disorder" Encyclopedia, https://encyclopedia.pub/entry/21265 (accessed December 13, 2024).
Molinaro, P., Nappi, R., , ., Bosoni, D., & Tiranini, L. (2022, April 01). Premenstrual Syndrome and Premenstrual Dysphoric Disorder. In Encyclopedia. https://encyclopedia.pub/entry/21265
Molinaro, Pietro, et al. "Premenstrual Syndrome and Premenstrual Dysphoric Disorder." Encyclopedia. Web. 01 April, 2022.
Premenstrual Syndrome and Premenstrual Dysphoric Disorder
Edit

Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) encompass a variety of symptoms that occur during the luteal phase of the menstrual cycle and impair daily life activities and relationships. Depending on the type and severity of physical, emotional or behavioral symptoms, women of reproductive age followed for at least two prospective menstrual cycles may receive one of the two diagnoses. PMDD is the most severe form of PMS, predominantly characterized by emotional and behavioral symptoms not due to another psychiatric disorder. PMS and PMDD are common neuro-hormonal gynecological disorders with a multifaceted etiology. Gonadal steroid hormones and their metabolites influence a plethora of biological systems involved in the occurrence of specific symptoms, but there is no doubt that PMS/PMDD are centrally based disorders. A more sensitive neuroendocrine threshold to cyclical variations of estrogens and progesterone under physiological and hormonal therapies is present. Moreover, altered brain sensitivity to allopregnanolone, a metabolite of progesterone produced after ovulation potentiating GABA activity, along with an impairment of opioid and serotoninergic systems, may justify the occurrence of emotional and behavioral symptoms. Even neuro-inflammation expressed via the GABAergic system is under investigation as an etiological factor of PMS/PMDD.

premenstrual syndrome premenstrual dysphoric disorder estrogen progesterone allopregnanolone combined hormonal contraception (CHC) serotonin reuptake inhibitors (SSRIs) sepranolone neuro-inflammation neurosteroids

1. Introduction

Periodic menstrual blood loss is the hallmark of womanhood from menarche to menopause and represents a clear biological sign of gonadal hormonal variation [1]. The menstrual lens allows a catamenial view of a multitude of symptoms and conditions related to reproductive function [2][3], which ultimately indicates female adaptive abilities in order to ensure fertility goals. However, menstruation is much more than a biological phenomenon and still represents a clear “gender gap”. Its significance has evolved over time and across culture encompassing intrapersonal and interpersonal aspects [1]. Currently, women have better control over their menstrual periodicity, but catamenial manifestations may generate a significant burden in daily living activities and a certain amount of stigma [4]. Extensive literature covers menstrual health in order to hormonally manage predictable pain syndromes, including menstrual headaches and other conditions associated with the menstrual cycle [5][6][7]. Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are common medical conditions lacking objective measures or laboratory testing to confirm the diagnosis [8]. The main challenges include the subjective nature of premenstrual symptoms and the variability of menstrual patters across different reproductive stages, which require adequate diagnostic self-report methods or semi-structured clinical interviews in routine practice [8].

2. Epidemiology and Risks Factors of PMS/PMDD

Premenstrual symptoms are very common, affecting about half of women in reproductive age worldwide [9]. However, prevalence rates vary widely in different studies and countries depending on samples, methods of investigation and diagnostic criteria. Disparities may also derive from genetic and socio-cultural factors, including diet and life-style, stressors, personal attitudes, coping behaviors, workload and family responsibilities [9]. Available surveys in community populations indicate that PMS affects 20–30% of women, whereas PMDD ranges between 1.2 and 6.4% [10], with black women being significantly less likely to experience PMDD and PMS than white women (odds ratio (OR) 0.44, 95% confidence interval (CI) 0.25–0.79 and OR 0.64, 95% CI 0.47–0.88, respectively), similarly to what is observed in other mental health disorders [11]. Both conditions significantly reduce quality of life and raise societal costs associated with decreased work productivity, work absenteeism and increased use of health care services [12]. Prevalence and impact of PMS/PMDD are strong priorities to implement preventive strategies in young women [13]. Health care providers (HCPs) should be aware that premenstrual symptoms might fluctuate over time with no clear impact of age or reproductive stage, apart from menopausal transition [14][15]. Another relevant factor is that combined oral contraceptives (COCs), the most studied type of combined hormonal contraception (CHC), may improve overall premenstrual symptomatology in women with PMS/PMDD, but not premenstrual depressive symptoms [16]. Behavioral risk factors, especially smoking and adiposity, are overrepresented in women with PMS/PMDD, confirming their link to emotional vulnerability. Indeed, smoking was associated with an increased risk of premenstrual disorders (OR = 1.56 (95% CI: 1.25–1.93)). Stratified by diagnosis, the effect size estimate was higher for PMDD (OR = 3.15 (95% CI: 2.20–4.52)) than for PMS (OR = 1.27 (95% CI: 1.16–1.39)) [17]. A strong linear relationship between body mass index (BMI) at baseline and risk of incident PMS, with each 1 kg/m2 increase in BMI associated with a significant 3% increase in PMS risk (95% confidence interval (CI) 1.01–1.05), was evident [18]. In particular, women with BMI ≥ 27.5 kg/m2 at baseline had significantly higher risks of PMS than women with BMI < 20 kg/m2, following adjustment for age, smoking, physical activity, and other factors [18]. Intake of alcohol was associated with a moderate increase in the risk of PMS (OR = 1.45, 95% CI: 1.17 to 1.79), especially heavy drinking (OR = 1.79, 95% CI: 1.39 to 2.32) as compared to no or light drinking [19]. Studies on the effect of exercise have many methodological biases with some suggesting improvement of premenstrual symptoms [20]. Other proven risk factors include traumatic events, which greatly increased the odds of developing PMDD at follow-up (OR = 4.2, 95% CI = 1.2 to 12.0). Likewise, a history of anxiety disorder (OR = 2.5, 95% CI = 1.1 to 5.5) and elevated daily conflict scores (OR = 1.6, 95% CI = 1.1 to 2.3) predicted PMDD [21]. Depression may be strongly comorbid [22][23], in particular postnatally [24], and women with PMDD should be considered a high-risk group for suicidality, including increased vulnerabilities for suicidal thoughts, ideation, plans and attempts [25]. Other comorbidities include eating disorders, mainly bulimia and binge eating [26], and migraine [27]. The co-occurrence with pathological manifestations displaying premenstrual exacerbations supports a common neuroendocrine etiology [2][3]. Medical conditions such as anemia and endocrine disorders (namely thyroid and adrenal dysfunctions and hyperprolactinemia) [28], as well as chronic pelvic pain, fibromyalgia and any other inflammatory disorders [29][30], may mimic PMS/PMDD symptoms. HCPs should make a differential diagnosis to establish an individualized treatment plan [3][8][28].

3. Neuroendocrine Aspects of PMS/PMDD

The most characteristic aspect of PMS/PMDD is the temporal relation between the appearance of symptoms and the menstrual phase, indicating a role for gonadal steroid hormones and their metabolites in influencing the plethora of biological systems that contribute to the adjustments required to fulfil reproductive goals. However, women with PMS/PMDD do not show abnormalities in the reproductive hormone release pattern; rather, they seem to display a more sensitive neuroendocrine threshold to cyclical variations of estrogens and progesterone [31][32], which may give origin to catamential symptoms and exacerbation of mood disorders during reproductive transitions [33][34]. Data on other circulating hormones (prolactin, testosterone, cortisol, dehydroepiandrosterone sulphate, and thyroxine) are discordant and fail to separate women with PMS/PMDD from controls. However, they may be relevant to some individual somatic symptoms, for instance cyclic mastalgia or water retention [28].
Many genetic and epigenetic factors influence the neuroendocrine threshold of premenstrual symptoms according to the biopsychosocial model. Severity of mood symptoms and associated distress should guide clinical judgement [8][28]. However, both HCPs and women have their personal view of the set point of such threshold, explaining variable epidemiology of PMS/PMDD symptoms [10]. If the diagnostic threshold is too high, clinically relevant premenstrual symptoms may be underestimated and PMS/PMDD remain untreated. If it is too low, paraphysiologic variations in menstrual cycle-related well-being can be over-treated (Figure 1). The central nervous system (CNS) is one of the main target tissues for reproductive hormones but it is also a source of neurosteroids, which are involved throughout genomic and non-genomic mechanisms in a vast array of CNS functions [35][36][37] far beyond the scope of the present overview. Here, the researchers report the key concepts relevant to the current understanding of pathophysiology and potential treatment targets of PMS/PMDD.
Figure 1. Neuroendocrine threshold and PMS/PMDD diagnosis.

Estrogens and Progesterone

Hormonal transitions are associated with reproductive mood disorders, whereas premenarchal girls and postmenopausal women do not experience PMS/PMDD in the absence of gonadal steroid fluctuations. The same is true when gonadal steroids are high and rather stable, as occurs in pregnancy [38]. In addition, premenstrual symptoms do not occur during anovulatory cycles and disappear in chemically and/or surgically castrated women [39]. Several mechanisms involving estrogen receptors polymorphisms may explain the vulnerability to reproductive mood disorders [40]. Fluctuations of gonadal steroids, in particular progesterone produced by the corpus luteum, are key factors for PMS/PMDD [32], given the synchrony with post-ovulatory phase and the reinstatement of symptoms during GnRH agonist treatment when add-back progesterone is administered [41]. However, many women experience premenstrual symptoms immediately after ovulation and during the early luteal phase, while others report an exacerbation only a few days before menstruation, irrespective of progesterone fluctuations [39]. Therefore, the importance of the progesterone to estrogens ratio has been also investigated, because estrogens may exert an antidepressant effect [42], and women with PMS/PMDD and healthy women have similar progesterone serum concentrations [32][43]. A recent study prospectively evaluated estrogen and progesterone levels in both early and late luteal phases in women with PMDD and the association of these levels with PMDD symptom severity [44]. In women with PMDD, estrogen levels were lower than the controls during the early luteal phase and displayed a significant interaction with early luteal progesterone, suggesting that low estrogen level could moderate the severity of PMDD symptoms following exposure to progesterone [44]. On the other hand, estradiol administration may provoke PMS-like complaints, similarly to progesterone administration alone or together with estrogens [41][45]. Moreover, PMS-like symptoms often persist after anovulation has been induced with COCs, suggesting that both the dose of estrogens and the type of progestins may be relevant to mood symptoms in vulnerable women [46]. Finally, postmenopausal women receiving combined hormonal replacement therapy (HRT) may experience PMS-like complaints despite stable levels of estradiol and progesterone [47]. Of note, administration of mifepristone, a progesterone receptor antagonist, did not reduce physical, emotional and/or behavioral manifestation of PMS or change the timing of these symptoms [48][49]. More recently, ulipristal acetate (UPA), a second-generation SPRM already employed for emergency contraception and for the treatment of uterine fibroids [50], was tested as a suitable option to ameliorate symptoms in women with PMDD. The first proof-of-concept randomized controlled trial on UPA at low chronic dosing (5 mg/day) showed improvement in emotional and behavioral symptoms of PMDD [51]. Interestingly, brain-imaging studies demonstrated a specific sensitivity to gonadal steroids, confirmed at the cellular level in women with PMDD [52][53], that appeared regulated by UPA in response to behavioral stimuli [54]. Whether UPA displays a positive effect on PMDD by blocking the progesterone receptor-mediated signaling or by preventing ovulation with more stable levels of gonadal steroids remains to be determined.
At present, the most commonly prescribed hormonal treatment for the management of both physical and affective symptoms of PMS is CHC, with the rationale of suppressing ovulation [28]. Temporary chemical castration with gonadotropin releasing hormone (GnRH) agonists also appeared to be an effective treatment in the management of PMS/PMDD, more on physical than psychological symptoms [55]. However, add-back therapies using a combination of estrogen and progestogen to minimize negative effects of prolonged low estrogenic state in fertile women may restore symptoms in PMDD women who are intolerant especially to progestogens [56].

References

  1. Critchley, H.O.; Babayev, E.; Bulun, S.E.; Clark, S.; Garcia-Grau, I.; Gregersen, P.K.; Kilcoyne, A.; Kim, J.-Y.J.; Lavender, M.; Marsh, E.E.; et al. Menstruation: Science and society. Am. J. Obstet. Gynecol. 2020, 223, 624–664.
  2. Roeder, H.J.; Leira, E.C. Effects of the Menstrual Cycle on Neurological Disorders. Curr. Neurol. Neurosci. Rep. 2021, 21, 34.
  3. Pinkerton, J.V.; Guico-Pabia, C.J.; Taylor, H.S. Menstrual cycle-related exacerbation of disease. Am. J. Obstet. Gynecol. 2010, 202, 221–231.
  4. Barrington, D.J.; Robinson, H.J.; Wilson, E.; Hennegan, J. Experiences of menstruation in high income countries: A systematic review, qualitative evidence synthesis and comparison to low- and middle-income countries. PLoS ONE 2021, 16, e0255001.
  5. Matteson, K.A.; Zaluski, K.M. Menstrual Health as a Part of Preventive Health Care. Obstet. Gynecol. Clin. N. Am. 2019, 46, 441–453.
  6. Tassorelli, C.; Greco, R.; Allena, M.; Terreno, E.; Nappi, R.E. Transdermal Hormonal Therapy in Perimenstrual Migraine: Why, When and How? Curr. Pain Headache Rep. 2012, 16, 467–473.
  7. Shulman, L.P. Gynecological Management of Premenstrual Symptoms. Curr. Pain Headache Rep. 2010, 14, 367–375.
  8. Ismaili, E.; Consensus Group of the International Society for Premenstrual Disorders; Walsh, S.; O’Brien, P.M.S.; Bäckström, T.; Brown, C.; Dennerstein, L.; Eriksson, E.; Freeman, E.W.; Ismail, K.M.K.; et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): Auditable standards for diagnosis and management of premenstrual disorder. Arch. Women’s Ment. Health 2016, 19, 953–958.
  9. Sattar, K. Epidemiology of Premenstrual Syndrome, A Systematic Review and Meta-Analysis Study. J. Clin. Diagn. Res. 2014, 8, 106–109.
  10. Yonkers, K.A.; Simoni, M.K. Premenstrual disorders. Am. J. Obstet. Gynecol. 2018, 218, 68–74.
  11. Pilver, C.E.; Kasl, S.; Desai, R.; Levy, B.R. Health advantage for black women: Patterns in pre-menstrual dysphoric disorder. Psychol. Med. 2011, 41, 1741–1750.
  12. Rapkin, A.J.; Winer, S.A. Premenstrual syndrome and premenstrual dysphoric disorder: Quality of life and burden of illness. Expert Rev. Pharm. Outcomes Res. 2009, 9, 157–170.
  13. Gao, M.; Gao, D.; Sun, H.; Cheng, X.; An, L.; Qiao, M. Trends in Research Related to Premenstrual Syndrome and Premenstrual Dysphoric Disorder From 1945 to 2018: A Bibliometric Analysis. Front. Public Health 2021, 9, 596128.
  14. Potter, J.; Bouyer, J.; Trussell, J.; Moreau, C. Premenstrual Syndrome Prevalence and Fluctuation over Time: Results from a French Population-Based Survey. J. Women’s Health 2009, 18, 31–39.
  15. Sander, B.; Gordon, J.L. Premenstrual Mood Symptoms in the Perimenopause. Curr. Psychiatry Rep. 2021, 23, 73.
  16. de Wit, A.E.; de Vries, Y.A.; de Boer, M.K.; Scheper, C.; Fokkema, A.; Janssen, C.A.; Giltay, E.J.; Schoevers, R.A. Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: Pairwise and network meta-analysis of randomized trials. Am. J. Obstet. Gynecol. 2021, 225, 624–633.
  17. Choi, S.H.; Hamidovic, A. Association Between Smoking and Premenstrual Syndrome: A Meta-Analysis. Front. Psychiatry 2020, 11, 575526.
  18. Bertone-Johnson, E.R.; Hankinson, S.E.; Willett, W.C.; Johnson, S.R.; Manson, J.E. Adiposity and the Development of Premenstrual Syndrome. J. Women’s Health 2010, 19, 1955–1962.
  19. Fernández, M.D.M.; Saulyte, J.; Inskip, H.; Takkouche, B. Premenstrual syndrome and alcohol consumption: A systematic review and meta-analysis. BMJ Open 2018, 8, e019490.
  20. Pearce, E.; Jolly, K.; Jones, L.; Matthewman, G.; Zanganeh, M.; Daley, A. Exercise for premenstrual syndrome: A systematic review and meta-analysis of randomised controlled trials. BJGP Open 2020, 4, 25.
  21. Perkonigg, A.; Yonkers, K.A.; Pfister, H.; Lieb, R.; Wittchen, H.-U. Risk Factors for Premenstrual Dysphoric Disorder in a Community Sample of Young Women: The role of traumatic events and posttraumatic stress disorder. J. Clin. Psychiatry 2004, 65, 1314–1322.
  22. Studd, J. Severe premenstrual syndrome and bipolar disorder: A tragic confusion. Menopause Int. 2012, 18, 82–86.
  23. Slyepchenko, A.; Minuzzi, L.; Frey, B.N. Comorbid Premenstrual Dysphoric Disorder and Bipolar Disorder: A Review. Front. Psychiatry 2021, 12, 719241.
  24. Pereira, D.; Pessoa, A.R.; Madeira, N.; Macedo, A.; Pereira, A.T. Association between premenstrual dysphoric disorder and perinatal depression: A systematic review. Arch. Women’s Ment. Health 2021, 25, 61–70.
  25. Osborn, E.; Brooks, J.; O’Brien, P.M.S.; Wittkowski, A. Suicidality in women with Premenstrual Dysphoric Disorder: A systematic literature review. Arch. Women’s Ment. Health 2021, 24, 173–184.
  26. Nobles, C.J.; Thomas, J.J.; Valentine, S.E.; Gerber, M.; Ba, A.S.V.; Marques, L. Association of premenstrual syndrome and premenstrual dysphoric disorder with bulimia nervosa and binge-eating disorder in a nationally representative epidemiological sample. Int. J. Eat. Disord. 2016, 49, 641–650.
  27. Nappi, R.E.; Nappi, G. Neuroendocrine aspects of migraine in women. Gynecol. Endocrinol. 2012, 28, 37–41.
  28. Stute, P.; Bodmer, C.; Ehlert, U.; Eltbogen, R.; Ging, A.; Streuli, I.; Von Wolff, M. Interdisciplinary consensus on management of premenstrual disorders in Switzerland. Gynecol. Endocrinol. 2017, 33, 342–348.
  29. Amital, D.; Herskovitz, C.; Fostick, L.; Silberman, A.; Doron, Y.; Zohar, J.; Itsekson, A.; Zolti, M.; Rubinow, A.; Amital, H. The Premenstrual Syndrome and Fibromyalgia—Similarities and Common Features. Clin. Rev. Allergy Immunol. 2010, 38, 107–115.
  30. Graziottin, A. The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval. Eur. J. Contracept. Reprod. Health Care 2016, 21, 93–105.
  31. Stahl, S.M. Estrogen Makes the Brain a Sex Organ. J. Clin. Psychiatry 1997, 58, 421–422.
  32. Backstrom, T.; Sanders, D.; Leask, R.; Davidson, D.; Warner, P.; Bancroft, J. Mood, Sexuality, Hormones, and the Menstrual Cycle. II. Hormone Levels and Their Relationship to the Premenstrual Syndrome. Psychosom. Med. 1983, 45, 503–507.
  33. Soares, C.N.; Zitek, B. Reproductive hormone sensitivity and risk for depression across the female life cycle: A continuum of vulnerability? J. Psychiatry Neurosci. 2008, 33, 331–343.
  34. Wise, D.D.; Felker, A.; Stahl, S.M. Tailoring treatment of depression for women across the reproductive lifecycle: The importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology. CNS Spectr. 2008, 13, 647–662.
  35. Genazzani, A.; Gastaldi, M.; Bidzinska, B.; Mercuri, N.; Nappi, R.; Segre, A.; Petraglia, F. The brain as a target organ of gonadal steroids. Psychoneuroendocrinology 1992, 17, 385–390.
  36. Bernardi, F.; Pluchino, N.; Stomati, M.; Pieri, M.; Genazzani, A.R. CNS: Sex Steroids and SERMs. Ann. N. Y. Acad. Sci. 2003, 997, 378–388.
  37. Giatti, S.; Diviccaro, S.; Serafini, M.M.; Caruso, D.; Garcia-Segura, L.M.; Viviani, B.; Melcangi, R.C. Sex differences in steroid levels and steroidogenesis in the nervous system: Physiopathological role. Front. Neuroendocr. 2019, 56, 100804.
  38. Schweizer-Schubert, S.; Gordon, J.L.; Eisenlohr-Moul, T.A.; Meltzer-Brody, S.; Schmalenberger, K.M.; Slopien, R.; Zietlow, A.-L.; Ehlert, U.; Ditzen, B. Steroid Hormone Sensitivity in Reproductive Mood Disorders: On the Role of the GABAA Receptor Complex and Stress During Hormonal Transitions. Front. Med. 2021, 7, 479646.
  39. Yonkers, K.A.; O’Brien, P.S.; Eriksson, E. Premenstrual syndrome. Lancet 2008, 371, 1200–1210.
  40. McEvoy, K.; Osborne, L.; Nanavati, J.; Payne, J.L. Reproductive Affective Disorders: A Review of the Genetic Evidence for Premenstrual Dysphoric Disorder and Postpartum Depression. Curr. Psychiatry Rep. 2017, 19, 94.
  41. Schmidt, P.J.; Nieman, L.K.; Danaceau, M.A.; Adams, L.F.; Rubinow, D.R. Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome. N. Engl. J. Med. 1998, 338, 209–216.
  42. Studd, J.W. A guide to the treatment of depression in women by estrogens. Climacteric 2011, 14, 637–642.
  43. Bixo, M.; Johansson, M.; Timby, E.; Michalski, L.; Bäckström, T. Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder. J. Neuroendocr. 2018, 30, e12553.
  44. Yen, J.-Y.; Lin, H.-C.; Liu, T.-L.; Long, C.-Y.; Ko, C.-H. Early- and Late-Luteal-Phase Estrogen and Progesterone Levels of Women with Premenstrual Dysphoric Disorder. Int. J. Environ. Res. Public Health 2019, 16, 4352.
  45. Bäckström, T.; Andreen, L.; Birzniece, V.; Björn, I.; Johansson, I.-M.; Nordenstam-Haghjo, M.; Nyberg, S.; Poromaa, I.S.; Wahlström, G.; Wang, M.; et al. The Role of Hormones and Hormonal Treatments in Premenstrual Syndrome. CNS Drugs 2003, 17, 325–342.
  46. Oinonen, K.A.; Mazmanian, D. To what extent do oral contraceptives influence mood and affect? J. Affect. Disord. 2002, 70, 229–240.
  47. Schmidt, P.J.; Rubinow, D.R. Sex Hormones and Mood in the Perimenopause. Ann. N. Y. Acad. Sci. 2009, 1179, 70–85.
  48. Chan, A.F.; Mortola, J.F.; Wood, S.H.; Yen, S.S. Persistence of premenstrual syndrome during low-dose administration of the pro-gesterone antagonist RU 486. Obstet. Gynecol. 1994, 84, 1001–1005.
  49. Schmidt, P.J.; Nieman, L.K.; Grover, G.N.; Muller, K.L.; Merriam, G.R.; Rubinow, D.R. Lack of Effect of Induced Menses on Symptoms in Women with Premenstrual Syndrome. N. Engl. J. Med. 1991, 324, 1174–1179.
  50. Critchley, H.O.D.; Chodankar, R.R. 90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies. J. Mol. Endocrinol. 2020, 65, T15–T33.
  51. Comasco, E.; Kallner, H.K.; Bixo, M.; Hirschberg, A.L.; Nyback, S.; de Grauw, H.; Epperson, C.N.; Sundström-Poromaa, I. Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial. Am. J. Psychiatry 2021, 178, 256–265.
  52. Baller, E.B.; Wei, S.-M.; Kohn, P.D.; Rubinow, D.R.; Alarcón, G.; Schmidt, P.J.; Berman, K.F. Abnormalities of Dorsolateral Prefrontal Function in Women with Premenstrual Dysphoric Disorder: A Multimodal Neuroimaging Study. Am. J. Psychiatry 2013, 170, 305–314.
  53. Wei, S.-M.; Baller, E.B.; Martinez, P.E.; Goff, A.C.; Li, H.J.; Kohn, P.D.; Kippenhan, J.S.; Soldin, S.J.; Rubinow, D.R.; Goldman, D.; et al. Subgenual cingulate resting regional cerebral blood flow in premenstrual dysphoric disorder: Differential regulation by ovarian steroids and preliminary evidence for an association with expression of ESC/E(Z) complex genes. Transl. Psychiatry 2021, 11, 206.
  54. Kaltsouni, E.; Fisher, P.M.; Dubol, M.; Hustad, S.; Lanzenberger, R.; Frokjaer, V.G.; Wikström, J.; Comasco, E.; Sundström-Poromaa, I. Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator. Neuropsychopharmacology 2021, 46, 1460–1467.
  55. Wyatt, K.M.; Dimmock, P.W.; O’Brien, P.S.; Ismail, K.M.; Jones, P.W. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: A meta analysis. BJOG Int. J. Obstet. Gynaecol. 2004, 111, 585–593.
  56. Segebladh, B.; Borgström, A.; Nyberg, S.; Bixo, M.; Sundström-Poromaa, I. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am. J. Obstet. Gynecol. 2009, 201, 139.e1–139.e8.
More
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , , ,
View Times: 565
Revisions: 2 times (View History)
Update Date: 02 Apr 2022
1000/1000
ScholarVision Creations